Who
Amy Parison
SVP, Chief Financial Officer
Company insider
Files Form 4 as: SVP, Chief Financial Officer, Editas Medicine.
In numbers
- Trades disclosed
- 15
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $15K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Apr 2025
- Last trade
- 3 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 4 Sep 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,376453 at $3.04 | filing |
| 3 Sep 2026filed 4 Sep 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,377453 at $3.04 | filing |
| 3 Aug 2026filed 5 Aug 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,749678 at $2.58 | filing |
| 3 Aug 2026filed 5 Aug 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,749678 at $2.58 | filing |
| 3 Jun 2026filed 5 Jun 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,253464 at $2.70 | filing |
| 3 Jun 2026filed 5 Jun 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,253464 at $2.70 | filing |
| 12 Mar 2026filed 16 Mar 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —292,856 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —292,856 at $0.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $957474 at $2.02 | filing |
| 3 Mar 2026filed 4 Mar 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $957474 at $2.02 | filing |
| 3 Dec 2025filed 4 Dec 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $991461 at $2.15 | filing |
| 3 Sep 2025filed 4 Sep 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,191458 at $2.60 | filing |
| 7 Aug 2025filed 8 Aug 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,752679 at $2.58 | filing |
| 3 Jun 2025filed 4 Jun 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $767446 at $1.72 | filing |
| 8 Apr 2025filed 8 Apr 2025 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —34,672 at $0.00 | filing |
News
Financial Contrast: Alvotech (NASDAQ:ALVO) & Editas Medicine (NASDAQ:EDIT)EDIT · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Amy Parison; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.